In addition, T cell activation via CD137 is known to increase metabolic capacity in tumor microenvironment and CD137 pretreatment is sufficient to provide metabolic support for a full anti–PD-1 response [85]. This evidence concerns the gene TNFRSF9 and neoplasm.